Clin Assoc Prof Tuan Kit Loong Jeffrey

Dr Jeffrey Tuan is a Senior Consultant and Head of the Department of Hepato-biliary-pancreato-Gastrointestinal and Urological Radiation Oncology, and Research Director in the Division of Radiation Oncology, at the National Cancer Centre Singapore. He also holds visiting consultant appointments in Urology at Singapore General Hospital and at the KK Gynaecological Cancer Centre, KK Women’s and Children’s Hospital, and is a Clinical Associate Professor in the Oncology Academic Clinical Programme at Duke-NUS Medical School. He specialises in prostate cancer radiotherapy, having treated over 1,000 patients using external beam radiotherapy, stereotactic body radiotherapy (SBRT), brachytherapy and proton beam therapy. Early in his career he spent four years on clinical and research fellowships at the Royal Marsden Hospital and Institute of Cancer Research in London, and at the Fondazione CNAO in Pavia, Italy, under the European Commission’s PARTNER network for particle therapy. He has since established a large prospective outcomes registry spanning around 10,000 patients over more than 10 years, and his research focuses on minimising treatment-related toxicity and preserving quality of life in prostate cancer, including work on intra-fractional motion mitigation, dose-accumulation modelling and focal dose escalation with proton therapy. In June 2026 he was appointed Discipline Representative – Radiation Oncology on the TROG Scientific Committee for a three-year term.

• FAMS, Academy of Medicine, Singapore (2010)
• MSc, University of London and Institute of Cancer Research (ICR), UK (2009)
• FRCR, Royal College of Radiologists, UK (2009)
• MBBS, National University of Singapore (NUS) (2000)  

• Discipline Representative – Radiation Oncology, TROG Scientific Committee (2026–present)
• Visiting Consultant, Urology, Singapore General Hospital
• Visiting Consultant, KK Gynaecological Cancer Centre, KK Women’s and Children’s Hospital
• Clinical Teacher, Lee Kong Chian School of Medicine, Nanyang Technological University
• Member, Singapore Cancer Society (SCS) Prostate Survivorship Advisory Board
• Chairman, Singapore Cancer Society Prostate Cancer Awareness Month (PCAM) (2021)  

• EU Marie Curie Fellow in Particle Therapy, PARTNER Network, Fondazione CNAO, Pavia, Italy (2010–2012)
• Health Manpower Development Plan (HMDP) Award, Royal Marsden Hospital, London, UK, for Clinical Oncology (2007–2009)  

• Site PI, pharmaceutical-sponsored trial of PSMA-targeted Lutetium-177 therapy for non-metastatic prostate cancer, combined with SBRT to metastases (ongoing)
• NRG-sponsored trial comparing SBRT for prostate cancer with and without pelvic lymph node irradiation (local IRB approval in progress)
• Outcomes research in cancer care
• Stereotactic body radiotherapy (SBRT) in prostate cancer
• Low dose rate (LDR) brachytherapy in prostate cancer
• High dose rate (HDR) brachytherapy in prostate cancer
• Feasibility of dominant intraprostatic lesion (DIL) boosting / dose escalation with proton beam therapy  

• Chen K, Wong TH, Tan YG, et al. Cardio-oncology in advanced prostate cancer. Front Oncol. 2024;14:1386597.
• Gatsinga R, Tan YG, Chen W, et al. Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings. Transl Androl Urol. 2024;13(9):1786-1794.
• Ong A, Knight K, Panettieri V, et al. Study on the focal boost to the dominant intraprostatic lesions using proton therapy in high-risk prostate cancer patients with pelvic lymph node irradiation: assessing toxicity using the accumulated dose fitted NTCP models. Int J Radiat Oncol Biol Phys. 2024;120(2 Suppl):e571.
• Ong ALK, Knight K, Panettieri V, et al. Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study. Front Oncol. 2023;13:1241711.
• Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A review of the current clinical evidence for loco-regional moderate hyperthermia in the adjunct management of cancers. Cancers (Basel). 2023;15(2):346.
• Ong ALK, Knight K, Panettieri V, et al. Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose. Front Oncol. 2022;12:1084311.
• Ong ALK, Knight K, Panettieri V, et al. Dose-volume analysis of planned versus accumulated dose as a predictor for late gastrointestinal toxicity in men receiving radiotherapy for high-risk prostate cancer. Phys Imaging Radiat Oncol. 2022;23:97-102.
• Tan JSH, Teh JYH, Tan LLY, et al. Efficacy, toxicity, and quality-of-life outcomes of ultra-hypofractionated radiotherapy in patients with localized prostate cancer: a single-arm phase 2 trial from Asia. Asia Pac J Clin Oncol. 2022;18(5):e346-e355.
• Lim VT, Gacasan AC, Tuan JKL, et al. Evaluation of inter- and intra-observer variations in prostate gland delineation using CT-alone vs CT/TPUS. Rep Pract Oncol Radiother. 2022;27(1):97-103.
• Ong A, Knight K, Panettieri V, et al. Development of an automated radiotherapy dose accumulation workflow for locally advanced high-risk prostate cancer – a technical report. J Med Radiat Sci. 2021;68(2):203-210.
• Pang EPP, Knight K, Park SY, et al. Duration-dependent margins for prostate radiotherapy – a practical motion mitigation strategy. Strahlenther Onkol. 2020;196(7):657-663.
• Kiljunen T, Akram S, Niemelä J, et al. A deep learning-based automated CT segmentation of prostate cancer anatomy for radiation therapy planning – a retrospective multicenter study. Diagnostics (Basel). 2020;10(11):959.